Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New web tool aims to empower patients on multiple medications

NCT ID NCT06956820

Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests a new online tool that gives patients taking five or more medications personalized information about drug interactions and genetic risks. 120 adults from four European countries will use the tool for 12 weeks and answer questionnaires about their understanding and confidence. The goal is to see if the tool helps patients feel more in control and reduces medication risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

132 people

The number who actually took part.

Started

Jul 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

In order to be eligible to participate in this study, a subject must meet all of the following crite-ria: * Polypharmacy defined as the use of 5 or more drugs * Start usage of at least one index drug according to the list in table 3. * Subject must be ≥ 18 years old * Subject is able and willing to take part and be followed-up for at least 12 weeks * Subject is able to donate blood or saliva * Subject has signed informed consent A potential subject who meets any of the following criteria will be excluded from participation in this study: * Pregnancy or lactating * Life expectancy estimated to be less than three months by treating clinical team * Unable to consent to the study * Unwilling to take part * Subject has no fixed address * Subject has previously been genotyped for PGx genes * Subject has no current general practitioner * Subject is, in the opinion of the Investigator, not suitable to participate in the study * Estimated glomerular filtration rate (MDRD) of less than 15 ml/min per 1,73m2 * Patients with advanced liver failure (stage Child-Pugh C)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polypharmacy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polypharmacy

Contacts and locations

Locations

  • Universitatsklinikum Aachen

    Aachen, 52074, Germany

  • Universitatsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • University Hospital Ljubljana

    Ljubjana, Slovenia

  • University Hospital Patras

    Pátrai, 26504, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.